{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension&page=23",
    "query": {
      "intervention": "Open Label Extension",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 2286,
    "total_pages": 229,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T09:24:47.331Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02702492",
      "title": "PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "NHL"
      ],
      "interventions": [
        {
          "name": "KPT-9274",
          "type": "DRUG"
        },
        {
          "name": "Niacin ER",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Karyopharm Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2016-06-08",
      "completion_date": "2021-01-26",
      "has_results": true,
      "last_update_posted_date": "2024-11-25",
      "last_synced_at": "2026-10-27T09:24:47.331Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02702492"
    },
    {
      "nct_id": "NCT07139834",
      "title": "Pattern Separation in Major Depressive Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Major Depressive Disorder (MDD)"
      ],
      "interventions": [
        {
          "name": "SSRI (escitalopram or sertraline)",
          "type": "DRUG"
        },
        {
          "name": "Extended-Release Memantine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jeffrey Miller",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 30,
      "start_date": "2026-06-01",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-27T09:24:47.331Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07139834"
    },
    {
      "nct_id": "NCT03793439",
      "title": "Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sarcoidosis, Pulmonary",
        "Sarcoidosis Lung",
        "Sarcoidosis"
      ],
      "interventions": [
        {
          "name": "Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial",
          "type": "DRUG"
        },
        {
          "name": "Spirometry",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "RNA Sequencing",
          "type": "GENETIC"
        },
        {
          "name": "Laboratory testing",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Corticosteroid",
          "type": "DRUG"
        },
        {
          "name": "Tofacitinib 5mg [Xeljanz] 1 year open-label extension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST",
        "GENETIC"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 5,
      "start_date": "2019-05-15",
      "completion_date": "2021-06-24",
      "has_results": true,
      "last_update_posted_date": "2022-02-18",
      "last_synced_at": "2026-10-27T09:24:47.331Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03793439"
    },
    {
      "nct_id": "NCT01958853",
      "title": "Prospective Evaluation of Reduced Impedance Noninvasive Cortical Electrostimulation (RINCE) to Reduce Fibromyalgia Effects - Extension Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fibromyalgia"
      ],
      "interventions": [
        {
          "name": "RINCE",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Cerephex Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "22 Years to 65 Years"
      },
      "enrollment_count": 23,
      "start_date": "2013-08",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2015-09-17",
      "last_synced_at": "2026-10-27T09:24:47.331Z",
      "location_count": 1,
      "location_summary": "Pontiac, Michigan",
      "locations": [
        {
          "city": "Pontiac",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01958853"
    },
    {
      "nct_id": "NCT05509400",
      "title": "Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Rimegepant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 813,
      "start_date": "2022-10-18",
      "completion_date": "2025-06-10",
      "has_results": true,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-10-27T09:24:47.331Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • Stamford, Connecticut • Lake City, Florida + 20 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Lake City",
          "state": "Florida"
        },
        {
          "city": "Ocoee",
          "state": "Florida"
        },
        {
          "city": "Ormond Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05509400"
    },
    {
      "nct_id": "NCT00641511",
      "title": "Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post Traumatic Stress Disorder (PTSD)"
      ],
      "interventions": [
        {
          "name": "SYN117 (nepicastat)",
          "type": "DRUG"
        },
        {
          "name": "Placebo comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael E. DeBakey VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2008-06",
      "completion_date": "2009-11",
      "has_results": false,
      "last_update_posted_date": "2019-08-21",
      "last_synced_at": "2026-10-27T09:24:47.331Z",
      "location_count": 3,
      "location_summary": "Tuscaloosa, Alabama • Charleston, South Carolina • Houston, Texas",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00641511"
    },
    {
      "nct_id": "NCT00491530",
      "title": "A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mixed Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "ABT-335",
          "type": "DRUG"
        },
        {
          "name": "rosuvastatin calcium",
          "type": "DRUG"
        },
        {
          "name": "simvastatin",
          "type": "DRUG"
        },
        {
          "name": "atorvastatin calcium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 310,
      "start_date": "2007-06",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2012-01-20",
      "last_synced_at": "2026-10-27T09:24:47.331Z",
      "location_count": 1,
      "location_summary": "Abbott Park, Illinois",
      "locations": [
        {
          "city": "Abbott Park",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00491530"
    },
    {
      "nct_id": "NCT07494045",
      "title": "Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CKD Stage 3",
        "CKD Stage 4",
        "Secondary Hyperparathyroidism",
        "VDI"
      ],
      "interventions": [
        {
          "name": "CTAP101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Month to 17 Years"
      },
      "enrollment_count": 40,
      "start_date": "2026-08-05",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-27T09:24:47.331Z",
      "location_count": 5,
      "location_summary": "Kansas City, Missouri • Columbus, Ohio • Philadelphia, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07494045"
    },
    {
      "nct_id": "NCT04905212",
      "title": "A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgA Nephropathy"
      ],
      "interventions": [
        {
          "name": "Telitacicept 160mg",
          "type": "DRUG"
        },
        {
          "name": "Telitacicept 240mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RemeGen Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2021-11-04",
      "completion_date": "2023-11-09",
      "has_results": false,
      "last_update_posted_date": "2023-12-06",
      "last_synced_at": "2026-10-27T09:24:47.331Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Sacramento, California • San Francisco, California + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04905212"
    },
    {
      "nct_id": "NCT01716312",
      "title": "Omalizumab for Lupus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erthematosus",
        "Sjogren's Syndrome"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 17,
      "start_date": "2014-01-08",
      "completion_date": "2017-08-24",
      "has_results": false,
      "last_update_posted_date": "2022-04-20",
      "last_synced_at": "2026-10-27T09:24:47.331Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01716312"
    }
  ]
}